Format

Send to

Choose Destination
See comment in PubMed Commons below
Med Sci (Paris). 2010 Jun-Jul;26(6-7):641-6. doi: 10.1051/medsci/2010266-7641.

[Could idiosyncratic thinking fit with << omics >>?].

[Article in French]

Author information

1
Université Paris-Descartes et Inserm U775, 75006 Paris, France. celine.narjoz@parisdescartes.fr

Abstract

Idiosyncratic toxicity is a rare adverse drug-induced reaction. It may occur in a small number of patients, is often serious and may lead to patients' death. Preclinical and clinical drug development fail to predict idiosyncratic post-marketing problems. Idiosyncratic adverse reaction could be prevented either by detection of predisposed patients or use of biomarkers that could predict adverse reactions induced by a drug. The identification of biomarkers that could help predict idiosyncratic reaction requires highthrouhput technologies such as << omics >> (genomic, transcriptomic, proteomic, metabonomic), which are methods allowing screening and evaluation of extensive data and are suitable for untargeted analyses of different models. This review presents genomic and transcriptomic data. The genomic studies identified genetic risk factor that could be used in clinical practice to prevent idiosyncratic reaction in predisposed patients. The transcriptomic studies gave information on biological processes altered by a treatment with a drug. Understanding toxicity mechanisms could lead to identification of toxicity biomarkers.

PMID:
20619168
DOI:
10.1051/medsci/2010266-7641
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for EDP Sciences
    Loading ...
    Support Center